HPV-SEQ detects and quantifies cell-free HPV 16 and 18 DNA (cfHPV-DNA) across a large dynamic range and demonstrates accurate quantification even when few copies are present.
HPV-SEQ enables high-resolution molecular monitoring of patients with HPV-driven cancers. Several studies are underway using HPV-SEQ to de-escalate HPV-driven cancer treatment to reduce toxicities without compromising survival outcomes. Assessment of quantitative cfHPV-DNA in the convenient biomarker-driven strategy to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC).1
The ability to reliably detect HPV-DNA in plasma at such low frequency shows HPV-SEQ could be a promising non-invasive biomarker test for effectively assessing treatment response, appropriately de-intensifying treatment using real-time dynamic HPV quantification, and monitoring HPV-positive OPC patients’ post-treatment. Therefore, the HPV-SEQ test has the potential to be an important tool for oncologists in treating patients with HPV-associated head and neck cancer,” he concluded.2
Dr. Nishant Agrawal,
Professor of Surgery at the University of Chicago
Panel features
CLIA-validated, ultra-sensitive quantitative blood test for the detection of cell-free HPV 16 and 18 DNA (cfHPV-DNA), this panel detects as few as 2 copies of HPV 16 and 18.
For clinicians only
References:
- Rosenberg A, Izumchenko E, Pearson A, Gooi Z, et al. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022. 3;22(1):17. doi: 10.1186/s12885-021-09146-z.
- Sysmex Inostics Press Release, January 26, 2022